Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

NCT07560488 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma
Conversion Therapy

Interventions

DRUG: Bevacizumab Biosimilar IBI305
DRUG: ipilimumab N01
DRUG: Sintilimab
DRUG: HAIC

Sponsor

Tianjin Medical University Cancer Institute and Hospital